港交所(00388.HK)委任黃莉娟爲董事總經理兼首次公開招股審查聯席主管
港交所(00388.HK)公佈,已委任黃莉娟爲董事總經理兼首次公開招股審查聯席主管。她將與劉穎共同負責監督所有上市申請,並一起領導經驗豐富的專業團隊,支持香港作爲全球上市首選市場的持續發展。
黃莉娟將於3月15日履新,並向港交所上市主管陳翊庭彙報。她接替將於3月底離開香港交易所,在集團外有其他發展的胡麗芬。
港交所上市主管陳翊庭表示,黃莉娟在過去二十多年爲多間投資銀行和企業就資本市場事宜提供專業諮詢,擁有豐富的領導和法律經驗。憑藉她的專業知識,將有助港交所繼續建設及提升香港的上市機制。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.